focus -WSS

focus

author：Wikipedia 2025-09-06 04:38:59 - browse：97

Medicare and money photo illustration. — Adobe

Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier.

CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

“I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

WSS

Lilly’s weekly insulin works as well as daily products, new studies show

What will Novo Nordisk's VC do with its influx of cash?

Medicare innovation center doesn’t save money, experts say

New oral drug delivery patch is modeled after octopus tentacles

RSV injection headlines need to be accurate for good uptake

As H5N1 spreads in cows, experts warn against drinking raw milk

explore

focus

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Experts study whether long Covid risk adds up with each reinfection

Jerome Adams on the need for new antivirals for Covid

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

In age of alternative facts, a scholarly course on calling out crap

Oak Street deal isn't the answer to health care's woes

Hollywood unions extend contract negotiations for actors

Study points to new risk in gene therapy death of Terry Horgan

Activists slam private health insurers over coverage restrictions

European officials brace for rough respiratory virus season

focus

Study points to new risk in gene therapy death of Terry Horgan

Some top drug companies are starting to take action on climate

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

What we owe ALS patients — and why one company fell short

HHS suspends federal funding for EcoHealth Alliance

hotspot

hotspot

focus

Wikipedia